Does higher stool zonulin reflect increased gut permeability and systemic inflammation?

The concept that intestinal barrier disruption drives systemic inflammation is highly supported by molecular evidence. However, the utility of stool zonulin as a direct surrogate for this process remains only plausible due to significant diagnostic limitations.

Intestinal permeability and microbial translocation

• Disruption of tight junction proteins—specifically the downregulation or mislocalization of ZO-1, occludin, and claudins—opens the paracellular pathway, letting luminal lipopolysaccharide (LPS) enter systemic circulation.
• This process is accelerated by a pathological feed-forward loop: translocated LPS binds to epithelial TLR4, activating MyD88/NF-κB/MLCK signaling to trigger cytoskeletal contraction and further tight junction disassembly.
• While transcellular translocation via chylomicrons occurs physiologically during dietary fat absorption, the non-selective paracellular route dominates during chronic barrier compromise.

Systemic immune activation and clinical impact

• Translocated LPS drives chronic "metabolic endotoxemia." Binding of picogram-to-nanogram concentrations of circulating LPS to TLR4 complexes on innate immune cells initiates MyD88- and TRIF-dependent signaling.
• This cascade activates downstream NF-κB and MAPKs, driving the systemic release of pro-inflammatory cytokines, including TNF-α, IL-1β, and IL-6.
• This persistent inflammatory state is clinically linked to insulin resistance, metabolic disease, and accelerated tissue or vascular damage.

Limitations of stool zonulin as a biomarker

• Despite zonulin's physiological role, stool zonulin correlates poorly and inconsistently with functional lactulose/mannitol tests at the individual level. Modest group-level correlations (r ≈ 0.3–0.4) occur in specific cohorts like obese individuals, but fail to generalize to other populations.
• Commercial ELISAs lack analytical specificity, frequently cross-reacting with other zonulin-related proteins (such as properdin) rather than measuring true pre-haptoglobin-2.

Bottom line

• Intestinal permeability directly drives paracellular LPS translocation and systemic TLR4-mediated inflammation, but stool zonulin is a weak, non-specific biomarker that cannot reliably quantify individual barrier dysfunction.